Use your browser's print dialog to print or save as PDF. This page is formatted for easy reading on paper.
MyPathologyReport Printed: November 20, 2026

HER2 in Colorectal Cancer

HER2 is a protein on the surface of cells that tells them to grow. In a small number of colorectal cancers, the cancer cells have extra copies of the gene that makes HER2. They then make far too much of the protein. These cancers are called HER2-positive. If a HER2-positive colorectal cancer has spread, drugs that target HER2 may help.

This article explains what a HER2 result means on your report, how the test is done, and how the result may affect your treatment.

What HER2 is and what it does

HER2 in colorectal cancer works like an antenna on the cell surface. It picks up signals that tell the cell to grow and divide. When a cancer cell has extra copies of the HER2 gene, it makes far too much HER2 protein, and the growth signal stays switched on. Drugs that block HER2 can turn that signal off.

Less often, the HER2 gene has a mutation, a change in the gene itself rather than extra copies. A mutation is a different finding, and this article explains it later. These HER2 changes happen only in the cancer cells and are not inherited.

How common is HER2-positive colorectal cancer?

About 3 to 5 in 100 colorectal cancers are HER2-positive. HER2-positive colorectal cancers tend to share three features:

Why is the test done?

HER2 testing in colorectal cancer is usually done when the cancer has spread. It helps your care team in two ways:

How the test is performed

HER2 testing in colorectal cancer is done on tissue from a biopsy or from surgery. Three kinds of tests can be used.

Immunohistochemistry (IHC)

Immunohistochemistry (IHC) stains the HER2 protein on a thin slice of the tumor so it can be seen under the microscope. A pathologist looks at how dark the staining is on the edge of the cancer cells and gives a score of 0, 1+, 2+, or 3+.

Laboratories use slightly different rules for how many cancer cells must be stained. Some require more than half of the cells to be stained. Others use a lower cut-off of 10% of the cells. In practice, both approaches almost always give the same final answer.

In situ hybridization (ISH or FISH)

In situ hybridization (ISH) counts the copies of the HER2 gene inside the cancer cells. One common form is called FISH. ISH is usually done when the IHC score is 2+. The report says the gene is either “amplified,” meaning extra copies are present, or “not amplified.”

Next-generation sequencing (NGS)

In colorectal cancer that has spread, a single next-generation sequencing (NGS) test often checks many genes at once, including KRAS, NRAS, BRAF, and HER2. NGS can detect extra copies of the HER2 gene and HER2 mutations. In colorectal cancer, extra copies found by NGS on tumor tissue can be enough to show that the cancer is HER2-positive.

NGS can also be done on a blood sample, called a liquid biopsy. Your care team will decide whether a blood result needs to be confirmed on tissue.

How results are reported

HER2 results in colorectal cancer may appear in your pathology report, a separate molecular report, or both:

What the result means

HER2-negative

A HER2-negative colorectal cancer is not expected to respond to drugs that target HER2. This is the most common result. Treatment is guided by your other test results, including RAS, BRAF, and mismatch repair (MMR), and by the cancer stage.

HER2 equivocal (score 2+)

A borderline HER2 result in colorectal cancer means the first test could not give a clear answer. ISH or NGS then decides. If the gene is amplified, the cancer is HER2-positive. If not, it is HER2-negative.

HER2-positive

A HER2-positive colorectal cancer depends partly on HER2 to grow, so drugs that target HER2 may help. Because these cancers usually have normal RAS and BRAF genes, anti-EGFR drugs might seem like a good choice. HER2 can make those drugs work less well, and your oncologist will weigh this when planning treatment.

HER2 mutation

About 4 in 100 colorectal cancers have a HER2 mutation. The approved HER2 treatments are for HER2-positive cancer, not for HER2 mutations. Clinical trials are studying treatments for HER2-mutant cancers, and your oncologist can tell you whether one may be an option.

Treatments linked to HER2-positive results

The US Food and Drug Administration (FDA) has approved drugs that target HER2 in colorectal cancer. They are used after other treatment, for cancer that cannot be removed with surgery or has spread. Approvals in other countries may differ.

Studies are now testing whether HER2-targeted drugs work better when given earlier, as part of first-line treatment. Ask your oncologist whether a clinical trial may be right for you.

HER2 and anti-EGFR treatment

HER2 matters for anti-EGFR treatment in colorectal cancer because it gives the cancer a second way to receive growth signals. Cetuximab and panitumumab block EGFR, but not HER2. A HER2-positive cancer can keep growing through HER2 even while EGFR is blocked. This is why many oncologists check HER2 before choosing anti-EGFR treatment.

Does HER2 status have hereditary implications?

HER2 changes in colorectal cancer happen only in the cancer cells and are not inherited. A HER2 result does not mean your family members have a higher risk of cancer. Inherited risk for colorectal cancer is checked in other ways, mainly through MMR testing for Lynch syndrome.

What happens next

What happens after HER2 testing in colorectal cancer depends on the final result:

HER2 can differ between the original tumor and the sites where the cancer has spread. If the cancer grows or a new biopsy is taken, doctors may test HER2 again.

Questions to ask your doctor

Related articles on MyPathologyReport.com